H.C. Wainwright mantiene calificación de Compra para acciones de Pharvaris con objetivo de 60 dólares
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema - Slideshow (NASDAQ:PHVS) 2025-12-09
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript